• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症患者 COVID-19 疾病严重程度的决定因素。

Determinants of COVID-19 disease severity in patients with cancer.

机构信息

Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Infection Control, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Nat Med. 2020 Aug;26(8):1218-1223. doi: 10.1038/s41591-020-0979-0. Epub 2020 Jun 24.

DOI:10.1038/s41591-020-0979-0
PMID:32581323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7785283/
Abstract

As of 10 April 2020, New York State had 180,458 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths. Patients with cancer comprised 8.4% of deceased individuals. Population-based studies from China and Italy suggested a higher coronavirus disease 2019 (COVID-19) death rate in patients with cancer, although there is a knowledge gap as to which aspects of cancer and its treatment confer risk of severe COVID-19. This information is critical to balance the competing safety considerations of reducing SARS-CoV-2 exposure and cancer treatment continuation. From 10 March to 7 April 2020, 423 cases of symptomatic COVID-19 were diagnosed at Memorial Sloan Kettering Cancer Center (from a total of 2,035 patients with cancer tested). Of these, 40% were hospitalized for COVID-19, 20% developed severe respiratory illness (including 9% who required mechanical ventilation) and 12% died within 30 d. Age older than 65 years and treatment with immune checkpoint inhibitors (ICIs) were predictors for hospitalization and severe disease, whereas receipt of chemotherapy and major surgery were not. Overall, COVID-19 in patients with cancer is marked by substantial rates of hospitalization and severe outcomes. The association observed between ICI and COVID-19 outcomes in our study will need further interrogation in tumor-specific cohorts.

摘要

截至 2020 年 4 月 10 日,纽约州有 180458 例严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)病例和 9385 例报告死亡。癌症患者占死亡人数的 8.4%。来自中国和意大利的基于人群的研究表明,癌症患者的 2019 年冠状病毒病(COVID-19)死亡率较高,尽管对于癌症及其治疗的哪些方面会导致 COVID-19 重症的风险,还存在知识差距。这些信息对于平衡减少 SARS-CoV-2 暴露和癌症治疗继续的安全考虑因素至关重要。从 2020 年 3 月 10 日至 4 月 7 日,纪念斯隆凯特琳癌症中心(对 2035 例癌症患者进行了总计检测)诊断出 423 例有症状的 COVID-19 病例。其中,40%的患者因 COVID-19 住院,20%的患者出现严重呼吸道疾病(包括 9%需要机械通气),12%的患者在 30 天内死亡。年龄大于 65 岁和接受免疫检查点抑制剂(ICI)治疗是住院和重症的预测因素,而接受化疗和大手术则不是。总的来说,癌症患者的 COVID-19 具有很高的住院和严重结局的发生率。在我们的研究中观察到的 ICI 与 COVID-19 结局之间的关联需要在肿瘤特异性队列中进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93e7/7785283/d904e37397c1/nihms-1611058-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93e7/7785283/d904e37397c1/nihms-1611058-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93e7/7785283/d904e37397c1/nihms-1611058-f0001.jpg

相似文献

1
Determinants of COVID-19 disease severity in patients with cancer.癌症患者 COVID-19 疾病严重程度的决定因素。
Nat Med. 2020 Aug;26(8):1218-1223. doi: 10.1038/s41591-020-0979-0. Epub 2020 Jun 24.
2
Determinants of Severity in Cancer Patients with COVID-19 Illness.新冠病毒病癌症患者病情严重程度的决定因素。
medRxiv. 2020 May 8:2020.05.04.20086322. doi: 10.1101/2020.05.04.20086322.
3
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.癌症患者 COVID-19 的患病率和死亡率,以及主要肿瘤亚型和患者人口统计学特征的影响:一项前瞻性队列研究。
Lancet Oncol. 2020 Oct;21(10):1309-1316. doi: 10.1016/S1470-2045(20)30442-3. Epub 2020 Aug 24.
4
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.癌症患者出现 COVID-19 症状,无论 RT-PCR 是否检测到 SARS-COV-2,死亡率均较高。
Eur J Cancer. 2020 Aug;135:251-259. doi: 10.1016/j.ejca.2020.05.028. Epub 2020 Jun 7.
5
Cohort of Four Thousand Four Hundred Four Persons Under Investigation for COVID-19 in a New York Hospital and Predictors of ICU Care and Ventilation.在纽约一家医院中对 4404 人进行的 COVID-19 调查队列研究,以及 ICU 护理和通气的预测因素。
Ann Emerg Med. 2020 Oct;76(4):394-404. doi: 10.1016/j.annemergmed.2020.05.011. Epub 2020 May 11.
6
Disease progression patterns and risk factors associated with mortality in deceased patients with COVID-19 in Hubei Province, China.中国湖北省 COVID-19 死亡患者疾病进展模式和与死亡率相关的因素。
Immun Inflamm Dis. 2020 Dec;8(4):584-594. doi: 10.1002/iid3.343. Epub 2020 Aug 28.
7
Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients With Coronavirus Disease 2019.空腹血糖受损和糖尿病与 2019 冠状病毒病患者的并发症和死亡率升高相关。
Front Endocrinol (Lausanne). 2020 Jul 10;11:525. doi: 10.3389/fendo.2020.00525. eCollection 2020.
8
COVID-19 in Padua, Italy: not just an economic and health issue.意大利帕多瓦的新冠肺炎疫情:不仅仅是经济和健康问题。
Nat Med. 2020 Jun;26(6):806. doi: 10.1038/s41591-020-0884-6.
9
Provision of cancer care during the COVID-19 pandemic.在 COVID-19 大流行期间提供癌症护理。
Nat Rev Clin Oncol. 2020 Jun;17(6):329-331. doi: 10.1038/s41571-020-0370-6.
10
Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic.在 COVID-19 大流行期间治疗癌症患者的实用考虑因素。
JCO Oncol Pract. 2020 Aug;16(8):467-482. doi: 10.1200/OP.20.00229. Epub 2020 May 13.

引用本文的文献

1
Circulating SARS-CoV-2 spike IgG antibody responses in cancer patients following multiple COVID-19 vaccination boosters.癌症患者多次接种新冠病毒疫苗加强针后的循环严重急性呼吸综合征冠状病毒2刺突蛋白IgG抗体反应
Front Immunol. 2025 Aug 12;16:1629473. doi: 10.3389/fimmu.2025.1629473. eCollection 2025.
2
Safety of immune checkpoint inhibitors in cancer patients with COVID-19: A review.免疫检查点抑制剂在新冠肺炎癌症患者中的安全性:综述
Medicine (Baltimore). 2025 Aug 8;104(32):e43579. doi: 10.1097/MD.0000000000043579.
3
Early mortality in patients with cancer and COVID-19 infection treated with immunotherapy.
接受免疫治疗的癌症合并新型冠状病毒肺炎感染患者的早期死亡率
BMC Cancer. 2025 May 22;25(1):922. doi: 10.1186/s12885-025-14318-2.
4
Differences in COVID-19-Related Hospitalization, Treatment, Complications, and Death by Race and Ethnicity and Area-Level Measures Among Individuals with Cancer in the ASCO Registry.美国临床肿瘤学会(ASCO)登记处中癌症患者因种族、民族及地区层面指标在与新冠病毒病(COVID-19)相关的住院治疗、并发症和死亡方面存在的差异。
Cancers (Basel). 2025 Mar 2;17(5):857. doi: 10.3390/cancers17050857.
5
Efficacy of Ayurvedic treatment given to cancer patients in the prevention of COVID-19 - A Retrospective Cohort Study at Integrated Cancer Treatment and Research Centre, Wagholi.阿育吠陀疗法对癌症患者预防COVID-19的疗效——瓦戈利综合癌症治疗与研究中心的一项回顾性队列研究
J Ayurveda Integr Med. 2025 Mar 5;16(2):101045. doi: 10.1016/j.jaim.2024.101045.
6
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.癌症患者中COVID-19 mRNA疫苗的预测生物标志物和特异性免疫反应:CACOV-VAC试验的前瞻性结果
BMJ Oncol. 2023 Dec 14;2(1):e000054. doi: 10.1136/bmjonc-2023-000054. eCollection 2023.
7
TIM3 in COVID-19; A potential hallmark?新冠病毒肺炎中的T细胞免疫球蛋白黏蛋白-3;一个潜在的标志?
Heliyon. 2024 Nov 13;10(23):e40386. doi: 10.1016/j.heliyon.2024.e40386. eCollection 2024 Dec 15.
8
Prognostic Factors for Survival or Severity After COVID-19 Infection in Cancer Patients: A Systematic Review and Meta-Analysis.癌症患者感染新型冠状病毒肺炎后的生存或严重程度的预后因素:一项系统评价和荟萃分析
J Rhinol. 2023 Jul;30(2):69-79. doi: 10.18787/jr.2023.00015. Epub 2023 Jul 28.
9
Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China.中国首次疫情期间接受 EGFR-TKI 靶向治疗的 NSCLC 患者感染 COVID-19 的风险。
J Int Med Res. 2024 Oct;52(10):3000605241281907. doi: 10.1177/03000605241281907.
10
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders.程序性死亡受体配体1:从癌症免疫疗法到在多种疾病中的治疗意义
Mol Ther. 2024 Dec 4;32(12):4235-4255. doi: 10.1016/j.ymthe.2024.09.026. Epub 2024 Sep 28.